Phenobarbital Oral Dosing
For children ≥4 years, adolescents, and adults requiring oral phenobarbital for seizure control, the recommended maintenance dosing is 1-3 mg/kg/day divided into 1-2 doses, with higher per-kilogram doses often necessary in pediatric patients to achieve therapeutic serum levels of 10-25 µg/mL.
Pediatric Dosing (Children ≥4 years and Adolescents)
Maintenance Therapy
- Standard maintenance dose: 3-5 mg/kg/day divided in 1-2 doses 1
- Higher doses often required: Children typically need 4-6 mg/kg/day to achieve therapeutic blood levels of 10-15 µg/mL 1
- Research demonstrates that children, especially those under 11 years, may require maintenance doses >5 mg/kg/day to reach the therapeutic range of 10-40 mg/L 2
Loading Dose (if applicable)
- 15-20 mg/kg produces blood levels of approximately 20 µg/mL shortly after administration 1
- This loading approach is primarily used in acute settings but establishes the foundation for maintenance therapy
Key Considerations for Pediatric Patients
- Weight-based dosing is essential: Actual body weight is the most well-founded covariate for phenobarbital dosing 3
- Younger children have higher clearance rates and require higher per-kilogram doses than adults 4, 2
- Therapeutic drug monitoring is strongly recommended to optimize dosing, as there is significant interindividual variability 4
Adult Dosing
Maintenance Therapy
- Daytime sedation/seizure control: 30-120 mg daily in 2-3 divided doses 1
- Typical maintenance range: 1-3 mg/kg/day divided into 1-2 doses
- For most adults, this translates to approximately 60-180 mg/day in divided doses
Loading Dose (if applicable)
- 15-20 mg/kg for acute seizure control or rapid therapeutic level achievement 1
Special Populations
Elderly Patients
- Dosage should be reduced due to age-related decline in renal function 1
- Start at the lower end of the dosing range and titrate carefully
- Increased sensitivity to barbiturates necessitates conservative dosing
Renal Impairment
- Dose reduction required for creatinine clearance <50 mL/min 1
- Phenobarbital clearance is significantly affected by renal function 4
Hepatic Impairment
- Dose reduction recommended as phenobarbital undergoes hepatic metabolism 1
Therapeutic Monitoring
Target serum concentration: 10-25 µg/mL for anticonvulsant effect 1
- Levels should be checked after steady state is achieved (approximately 2-3 weeks)
- Higher levels (up to 40 µg/mL) may be tolerated in some patients but increase risk of adverse effects 5
- Significant interindividual variability exists, particularly in critically ill patients (coefficient of variation >40% for clearance) 6
Administration Considerations
Oral Formulations
- Tablets and elixir formulations show no significant difference in bioavailability 2
- Oral bioavailability is approximately 96%, making oral and IV dosing essentially equivalent for maintenance therapy 6
- Can be administered with or without food
Dosing Frequency
- Once or twice daily dosing is appropriate due to long half-life (approximately 100 hours in adults)
- Divided dosing may improve tolerability in some patients
Common Pitfalls to Avoid
- Underdosing pediatric patients: Children require higher per-kilogram doses than adults; don't simply extrapolate adult dosing
- Failing to account for drug interactions: Concurrent antiepileptic drugs significantly affect phenobarbital clearance and may require dose adjustments 4, 2
- Inadequate monitoring: The wide interindividual variability necessitates therapeutic drug monitoring rather than relying solely on weight-based dosing
- Abrupt discontinuation: Phenobarbital must be tapered gradually (typically 10% reduction every few days) to avoid withdrawal seizures 1
- Ignoring renal/hepatic function: Failure to adjust doses in organ dysfunction leads to toxicity
Drug Interactions
Phenobarbital is a potent enzyme inducer and interacts with numerous medications. Dose adjustments may be necessary when:
- Adding or removing other antiepileptic drugs
- Starting medications metabolized by CYP450 enzymes
- The dose ratio (concentration/dose) is significantly higher in patients receiving combination antiepileptic therapy 2